https://www.selleckchem.com/products/compound-3i.html Colorectal cancer (CRC) remains a significant cause of morbidity and mortality in the US. To systematically review the effectiveness, test accuracy, and harms of screening for CRC to inform the US Preventive Services Task Force. MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials for relevant studies published from January 1, 2015, to December 4, 2019; surveillance through March 26, 2021. English-language studies conducted in asymptomatic populations at general risk of CRC. Two reviewers independently appraised the articles and extracted relevant study data from fair- or good-quality studies. Random-effects meta-analyses were conducted. Colorectal cancer incidence and mortality, test accuracy in detecting cancers or adenomas, and serious adverse events. The review included 33 studies (n = 10 776 276) on the effectiveness of screening, 59 (n = 3 491 045) on the test performance of screening tests, and 131 (n = 26 987 366) on the harms of screening. In randomized clinical trialability to detect cancer or precursor lesions, and its risk of harms. The US Preventive Services Task Force (USPSTF) is updating its 2016 colorectal cancer screening recommendations. To provide updated model-based estimates of the benefits, burden, and harms of colorectal cancer screening strategies and to identify strategies that may provide an efficient balance of life-years gained (LYG) from screening and colonoscopy burden to inform the USPSTF. Comparative modeling study using 3 microsimulation models of colorectal cancer screening in a hypothetical cohort of 40-year-old US individuals at average risk of colorectal cancer. Screening from ages 45, 50, or 55 years to ages 70, 75, 80, or 85 years with fecal immunochemical testing (FIT), multitarget stool DNA testing, flexible sigmoidoscopy alone or with FIT, computed tomography colonography, or colonoscopy. All persons with an abnormal noncolonoscopy screening test result